<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39189801</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-1504</ISSN><JournalIssue CitedMedium="Internet"><Volume>327</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>American journal of physiology. Lung cellular and molecular physiology</Title><ISOAbbreviation>Am J Physiol Lung Cell Mol Physiol</ISOAbbreviation></Journal><ArticleTitle>Developing a mouse model of human coronavirus NL63 infection: comparison with rhinovirus-A1B and effects of prior rhinovirus infection.</ArticleTitle><Pagination><StartPage>L557</StartPage><EndPage>L573</EndPage><MedlinePgn>L557-L573</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1152/ajplung.00149.2023</ELocationID><Abstract><AbstractText>Human coronavirus (HCoV)-NL63 causes respiratory tract infections in humans and uses angiotensin-converting enzyme 2 (ACE2) as a receptor. We sought to establish a mouse model of HCoV-NL63 and determine whether prior rhinovirus (RV)-A1B infection affected HCoV-NL63 replication. HCoV-NL63 was propagated in LLC-MK2 cells expressing human ACE2. RV-A1B was grown in HeLa-H1 cells. C57BL6/J or transgenic mice expressing human ACE2 were infected intranasally with sham LLC-MK2 cell supernatant or 1 × 10<sup>5</sup> tissue culture infectious dose (TCID<sub>50</sub>) units HCoV-NL63. Wild-type mice were infected with 1 × 10<sup>6</sup> plaque-forming units (PFU) RV-A1B. Lungs were assessed for vRNA, bronchoalveolar lavage (BAL) cells, histology, HCoV-NL63 nonstructural protein 3 (nsp3), and host gene expression by next-generation sequencing and qPCR. To evaluate sequential infections, mice were infected with RV-A1B followed by HCoV-NL63 infection 4 days later. We report that hACE2 mice infected with HCoV-NL63 showed evidence of replicative infection with increased levels of vRNA, BAL neutrophils and lymphocytes, peribronchial and perivascular infiltrates, and expression of nsp3. Viral replication peaked 3 days after infection and inflammation persisted 6 days after infection. HCoV-NL63-infected hACE2 mice showed increased mRNA expression of IFNs, IFN-stimulated proteins, and proinflammatory cytokines. Infection with RV-A1B 4 days before HCoV-NL63 significantly decreased both HCoV-NL63 vRNA levels and airway inflammation. Mice infected with RV-A1B prior to HCoV-NL63 showed increased expression of antiviral proteins compared with sham-treated mice. In conclusion, we established a mouse model of HCoV-NL63 replicative infection characterized by relatively persistent viral replication and inflammation. Prior infection with RV-A1B reduced HCoV-NL63 replication and airway inflammation, indicative of viral interference.<b>NEW &amp; NOTEWORTHY</b> We describe a mouse model of human coronavirus (HCoV) infection. Infection of transgenic mice expressing human angiotensin-converting enzyme 2 (ACE2) with HCoV-NL63 produced a replicative infection with peribronchial inflammation and nonstructural protein 3 expression. Mice infected with RV-A1B 4 days before HCoV-NL63 showed decreased HCoV-NL63 replication and airway inflammation and increased expression of antiviral proteins compared with sham-treated mice. This research may shed light on human coronavirus infections, viral interference, and viral-induced asthma exacerbations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bentley</LastName><ForeName>J Kelley</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kreger</LastName><ForeName>Jordan E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breckenridge</LastName><ForeName>Haley A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Shilpi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yiran</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Susan C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lumeng</LastName><ForeName>Carey N</ForeName><Initials>CN</Initials><Identifier Source="ORCID">0000-0003-0303-6204</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor, Michigan, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hershenson</LastName><ForeName>Marc B</ForeName><Initials>MB</Initials><Identifier Source="ORCID">0000-0001-9436-5593</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor, Michigan, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AI120526</GrantID><Agency>HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</Agency><Country /></Grant><Grant><GrantID>AI155444</GrantID><Agency>HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</Agency><Country /></Grant><Grant><GrantID>159945</GrantID><Agency>HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</Agency><Country /></Grant><Grant><Agency>Elizabeth Weiser Caswell COVID-19 and Metabolic Disease Grant Program</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Physiol Lung Cell Mol Physiol</MedlineTA><NlmUniqueID>100901229</NlmUniqueID><ISSNLinking>1040-0605</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000623787">Rhinovirus A</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058957" MajorTopicYN="Y">Coronavirus NL63, Human</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012229" MajorTopicYN="Y">Rhinovirus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010850" MajorTopicYN="Y">Picornaviridae Infections</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="Y">Angiotensin-Converting Enzyme 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="Y">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001992" MajorTopicYN="N">Bronchoalveolar Lavage Fluid</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">asthma</Keyword><Keyword MajorTopicYN="N">coronavirus</Keyword><Keyword MajorTopicYN="N">interference</Keyword><Keyword MajorTopicYN="N">interferon</Keyword><Keyword MajorTopicYN="N">rhinovirus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>27</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>27</Day><Hour>9</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39189801</ArticleId><ArticleId IdType="doi">10.1152/ajplung.00149.2023</ArticleId></ArticleIdList></PubmedData></PubmedArticle>